<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956484</url>
  </required_header>
  <id_info>
    <org_study_id>LXM-210622</org_study_id>
    <nct_id>NCT04956484</nct_id>
  </id_info>
  <brief_title>Belimumab In Treatment of Early Systemic Lupus Erythematosus</brief_title>
  <official_title>A Single-center, Randomized, Open Label, 52-week Study of Belimumab In Treatment of Early Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and impact on B cell subsets of belimumab in early SLE&#xD;
      patients(disease duration less than 3 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, randomized, open label, 52-week clinical trial. All 84 patients will&#xD;
      be randomly assigned in a 1:1 ratio with the use of standard of care plus Belimumab (at a&#xD;
      dose of 10 mg per kilogram of body weight) or standard of care alone.&#xD;
&#xD;
      The primary endpoint is the response rate of SLEDAI in 52 weeks. SLEDAI response was defined&#xD;
      as a ≥ 4-point reduction in SELENA-SLEDAI score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of SLEDAI</measure>
    <time_frame>52 weeks</time_frame>
    <description>SLEDAI response was defined as a ≥ 4-point reduction in SELENA-SLEDAI score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SRI-4</measure>
    <time_frame>52 weeks</time_frame>
    <description>Systemic lupus response index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flare of lupus disease</measure>
    <time_frame>52 weeks</time_frame>
    <description>the flare of disease during the treatment period will be defined and measured by SLE flare index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serologies</measure>
    <time_frame>24 weeks and 52 weeks</time_frame>
    <description>Changes in titers of anti-DNA antibody levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement levels</measure>
    <time_frame>24 weeks and 52 weeks</time_frame>
    <description>Changes in measures of C3, C4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamics of immune cell subsets</measure>
    <time_frame>24 weeks and 52 weeks</time_frame>
    <description>T cell and B cell subsets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid tapering</measure>
    <time_frame>24 weeks</time_frame>
    <description>A prednisone dose that was decreased≤ 10 mg/d</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Belimumab 10 mg/kg plus standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care and Belimumab: 10 mg per kilogram of body weight，days 1 (baseline), 15, and 29 and every 28 days thereafter to week 52</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard of care: Steroid(≤1mg/kg/d) with or without proper immunosuppressants which doctors prescribed，including CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Belimumab</intervention_name>
    <description>Belimumab 10 mg/kg plus standard therapy</description>
    <arm_group_label>Belimumab 10 mg/kg plus standard of care</arm_group_label>
    <other_name>BENLYSTA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.</description>
    <arm_group_label>Belimumab 10 mg/kg plus standard of care</arm_group_label>
    <arm_group_label>Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of SLE according to the 1997 American College of Rheumatology (ACR)&#xD;
             classification criteria or 2019 EULAR/ACR classification criteria within three months,&#xD;
             which is autoantibody-positive (antinuclear antibody titers ≥1:80,&#xD;
             anti-double-stranded DNA antibodies, or both)&#xD;
&#xD;
          -  18-75 years of age&#xD;
&#xD;
          -  body weight 45-80kg&#xD;
&#xD;
          -  Disease duration of SLE ≤ 3months&#xD;
&#xD;
          -  SELENA-SLEDAI score ≥8 scores&#xD;
&#xD;
          -  Negative pregnancy test for child-bearing women at screening and baseline&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known to be allergic to Prednisone Acetate, Meprednisone, Hydroxychloroquine, and&#xD;
             Immunosuppressants including Mycophenolate Mofetil, Cyclophosphamide,et al&#xD;
&#xD;
          -  Active serious neuropsychiatric systemic lupus erythematosus or other severe&#xD;
             situations of SLE who need pulse steroid treatment&#xD;
&#xD;
          -  Abnormal liver function (ALT or AST is 2 times higher than normal)&#xD;
&#xD;
          -  Pregnancy or breastfeeding women;&#xD;
&#xD;
          -  Have a history of malignant tumors;&#xD;
&#xD;
          -  Have any serious acute, chronic or recurrent infectious disease (such as pneumonia or&#xD;
             active stage of pyelitis, recurrent pneumonia, chronic bronchiectasis and&#xD;
             tuberculosis)&#xD;
&#xD;
          -  Chronic infections, such as Hepatitis B virus or hepatitis B and C and HIV;&#xD;
&#xD;
          -  Previous visual obstruction, monocular dysfunction and cataract;&#xD;
&#xD;
          -  Cardiac insufficiency with metabolic imbalance or severe high blood pressure (systolic&#xD;
             pressure &gt; 160mmHg or diastolic pressure &gt; 100mmHg) or diabetics;&#xD;
&#xD;
          -  Physicians will decide whether to use drugs if routine blood test is abnormal&#xD;
             WBC&lt;2x109/L or HGB&lt;60g/L or PLT&lt;50x109/L;&#xD;
&#xD;
          -  Active hemorrhage or peptic ulcer;&#xD;
&#xD;
          -  With other concommitant autoimmune disease;&#xD;
&#xD;
          -  Receipt of B-cell-targeted therapy (including belimumab) within 1 year before&#xD;
             randomization.&#xD;
&#xD;
          -  Participated in other drugs clinical trials within 4 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaomei Leng, MD</last_name>
    <phone>+86 13681057089</phone>
    <email>lpumch@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College hospital</name>
      <address>
        <city>Beijing</city>
        <state>Dongcheng</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaomei Leng</last_name>
      <phone>+86 13681057089</phone>
      <email>lpumch@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.</citation>
    <PMID>32937045</PMID>
  </reference>
  <reference>
    <citation>Gatto M, Saccon F, Zen M, Regola F, Fredi M, Andreoli L, Tincani A, Urban ML, Emmi G, Ceccarelli F, Conti F, Bortoluzzi A, Govoni M, Tani C, Mosca M, Ubiali T, Gerosa M, Bozzolo E, Canti V, Cardinaletti P, Gabrielli A, Tanti G, Gremese E, De Marchi G, De Vita S, Fasano S, Ciccia F, Pazzola G, Salvarani C, Negrini S, Puppo F, Di Matteo A, De Angelis R, Orsolini G, Rossini M, Faggioli P, Laria A, Piga M, Mathieu A, Scarpato S, Rossi FW, de Paulis A, Brunetta E, Ceribelli A, Selmi C, Prete M, Racanelli V, Vacca A, Bartoloni E, Gerli R, Larosa M, Iaccarino L, Doria A. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. Arthritis Rheumatol. 2020 Aug;72(8):1314-1324. doi: 10.1002/art.41253. Epub 2020 Jun 12.</citation>
    <PMID>32275125</PMID>
  </reference>
  <reference>
    <citation>Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.</citation>
    <PMID>21296403</PMID>
  </reference>
  <reference>
    <citation>Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, Catoggio LJ, Drenkard C, Sarano J, Berbotto GA, Borba EF, Sato EI, Tavares Brenol JC, Uribe O, Ramirez Gómez LA, Guibert-Toledano M, Massardo L, Cardiel MH, Silveira LH, Chacón-Diaz R, Alarcón GS, Pons-Estel BA; GLADEL. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis. 2017 Dec;76(12):2071-2074. doi: 10.1136/annrheumdis-2017-211814. Epub 2017 Sep 22.</citation>
    <PMID>28939626</PMID>
  </reference>
  <reference>
    <citation>Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018 Mar;77(3):355-363. doi: 10.1136/annrheumdis-2017-211631. Epub 2018 Jan 2.</citation>
    <PMID>29295825</PMID>
  </reference>
  <reference>
    <citation>Jackson SW, Davidson A. BAFF inhibition in SLE-Is tolerance restored? Immunol Rev. 2019 Nov;292(1):102-119. doi: 10.1111/imr.12810. Epub 2019 Sep 28. Review.</citation>
    <PMID>31562657</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <keyword>Belimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

